Comparing Nemluvio vs Nemolizumab
| Nemluvio (nemolizumab) | Nemolizumab |
|
|---|
| Nemluvio (nemolizumab) | Nemolizumab |
|
|||||||
|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Prurigo Nodularis, Atopic Dermatitis. Nemluvio may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Prurigo Nodularis, Atopic Dermatitis. Nemolizumab may also be used for purposes not listed in this medication guide. |
Related suggestions Atopic Dermatitis
|
|||||||
| More about Nemluvio (nemolizumab) | More about Nemolizumab | ||||||||
| Ratings & Reviews | |||||||||
|
Nemluvio has an average rating of 10.0 out of 10 from a total of 4 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
Nemolizumab has an average rating of 10.0 out of 10 from a total of 4 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | |||||||||
|
View all Nemluvio side effects |
View all Nemolizumab side effects |
||||||||
| Drug Class | |||||||||
| Generic Availability | |||||||||
|
N/A |
N/A |
||||||||
| Pricing and Coupons * Prices are without insurance | |||||||||
View all Nemluvio prices |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
||||||||
| Dosage Forms | |||||||||
|
N/A |
||||||||
| Brand Names | |||||||||
|
N/A |
Nemluvio | ||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | |||||||||
|
453.6 hours |
453.6 hours |
||||||||
| CSA Schedule 1 View glossary of CSA terms | |||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||
| Pregnancy Category | |||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||
| Drug Interactions | |||||||||
|
A total of 151 drugs are known to interact with Nemluvio:
|
A total of 151 drugs are known to interact with Nemolizumab:
|
||||||||
| Alcohol/Food/Lifestyle Interactions | |||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||
| Disease Interactions | |||||||||
| First Approval Date | |||||||||
|
August 12, 2024 |
N/A |
||||||||
| WADA Class View classifications | |||||||||
|
N/A |
N/A |
||||||||
| More Information | |||||||||
| Patient Resources | |||||||||
| Professional Resources | |||||||||
| Related Treatment Guide | |||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Actemra
Actemra is used to treat COVID-19, rheumatoid arthritis, systemic juvenile idiopathic arthritis ...
Adbry
Adbry is used to treat moderate-to-severe atopic dermatitis (eczema) in adults and children aged 12 ...
Dupixent
Dupixent is used to treat eczema, eosinophilic or oral-corticosteroid-dependent asthma, chronic ...
Arcalyst
Arcalyst (rilonacept) is used to treat Cryopyrin-Associated Periodic Syndromes, Deficiency of ...
Bimzelx
Bimzelx (bimekizumab) treats plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and ...
Cinqair
Cinqair (reslizumab) is a monoclonal antibody that affects the actions of the body's immune system ...
Cosentyx
Cosentyx (secukinumab) is used to treat plaque psoriasis, psoriatic arthritis, ankylosing ...
Dupilumab
Dupilumab injection is used to treat eczema, eosinophilic or oral-corticosteroid-dependent asthma ...
Ebglyss
Ebglyss (lebrikizumab) is a treatment for moderate-to-severe atopic dermatitis given as a monthly ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.